Metastatic Breast Cancer

In this video, Aruna Padmanabhan, MD, discusses the effectiveness of cyclin-dependent kinase inhibitors in the treatment of metastatic hormone-positive breast cancer.

Cannabidiol may reduce scan-related anxiety among women with advanced breast cancer, according to results of randomized phase 2 study results.

A qualitative study yielded important insights about how patients, caregivers and clinicians define what truly is clinically meaningful.

The FDA expanded the approval of trastuzumab deruxtecan for treatment of breast cancer.

Women diagnosed with advanced breast cancer appeared more likely than those with earlier-stage breast cancer to have pre-existing cardiovascular disease, according to results of a retrospective study.

In this episode of Meeting Mic, we bring you the highlights and insights from the San Antonio Breast Cancer Symposium 2024, as well as Healio’s top headlines from the meeting.

SAN ANTONIO — In this video, Shimoli Barot, MD, discusses the results of a study observing exceptional treatment response in patients with metastatic breast cancer presented at San Antonio Breast Cancer Symposium.

SAN ANTONIO — The addition of palbociclib to standard care extended median PFS for patients with hormone receptor-positive, HER2-positive metastatic breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.

SAN ANTONIO — The addition of pyrotinib to first-line trastuzumab and docetaxel improved PFS among patients with HER2-positive metastatic breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.

The detection of specific genomic alterations in circulating tumor DNA appeared linked to poorer outcomes among women with metastatic breast cancer, according to study results.